| Not Yet Recruiting | Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma NCT07479628 | Shanghai Chest Hospital | Phase 2 |
| Not Yet Recruiting | Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis NCT07328074 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Not Yet Recruiting | Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma NCT07324629 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors NCT07181720 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma NCT06838910 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | Survival Nomogram for Patients With Thymic Carcinoma NCT07179341 | Weijie Ye | N/A |
| Recruiting | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors NCT06248515 | Georgetown University | Phase 2 |
| Recruiting | Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) NCT06402708 | Fudan University | Phase 3 |
| Unknown | Neoadjuvant Treatment For Locally Advanced Thymic Cancer NCT06019468 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Recruiting | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors NCT06301945 | Erasmus Medical Center | — |
| Terminated | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors NCT04925947 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Ca NCT04469725 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Phase 2 |
| Completed | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S NCT04430842 | Quadriga Biosciences, Inc. | Phase 1 |
| Unknown | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) NCT03921671 | Claudia Proto | Phase 2 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Completed | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors NCT03583086 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic NCT03463460 | Dwight Owen | Phase 2 |
| Unknown | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) NCT03134118 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Active Not Recruiting | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic NCT03076554 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Tri NCT03449173 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Unknown | Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer NCT03170804 | Aventura Hospital and Medical Center | — |
| Recruiting | Molecular Analysis and Treatment Options of Thymic Malignancies NCT05667948 | Shanghai Chest Hospital | — |
| Completed | A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma NCT02623127 | Seoul National University Hospital | Phase 2 |
| Unknown | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma NCT02364076 | Georgetown University | Phase 2 |
| Completed | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy NCT02307500 | Istituto Clinico Humanitas | Phase 2 |
| Terminated | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy NCT02062632 | Mayo Clinic | Phase 2 |
| Enrolling By Invitation | Molecular Analysis of Thoracic Malignancies NCT01385722 | Stanford University | — |
| Completed | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies NCT01364727 | Heather Wakelee | Phase 2 |
| Terminated | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients U NCT01143545 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in th NCT01100944 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma NCT01011439 | Tiziana Life Sciences LTD | Phase 2 |
| Active Not Recruiting | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thym NCT01025089 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously T NCT00965250 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Paclitaxel and Cisplatin for Thymic Neoplasm NCT00818090 | Korean Cancer Study Group | Phase 2 |
| Completed | Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage NCT00589290 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma NCT00314873 | Indiana University School of Medicine | Phase 1 |
| Completed | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma NCT00198133 | Patrick Joseph Loehrer Sr. | Phase 2 |
| Completed | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma NCT00010257 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Meta NCT00003662 | Roswell Park Cancer Institute | Phase 2 |